Leading Specialty Pharmaceutical Manufacturer Selects Model N Revenue Management Suite to Improve Margins and Manage Compliance Risk

Share Article

Adoption Reflects Model N's Status as the Proven Solutions Provider for Integrating Commercial and Regulatory Processes

Legislative mandates such as the MMA and Medicare Part D have created commercial and government contracting overlaps like never before

Model N, Inc., a leader in Revenue Management solutions, today announced that a leading specialty pharmaceutical manufacturer has chosen Model N's Revenue Management Suite to boost margins and mitigate regulatory risk. The selection underscores the accelerating adoption of Model N's fully integrated regulatory and commercial solutions in the pharmaceutical industry.

To stay ahead of the competition in an increasingly complex and regulated life sciences business climate, the company decided it needed to overhaul its core revenue management capabilities. The company sought a scalable, industry-tailored solution that would optimize contracting processes and create a robust compliance infrastructure. After performing extensive diligence on competitive offerings, the company opted to partner with Model N due to its best-of-breed technology, deep domain expertise, and superior vision.

In addition to automating all facets of its pricing, contracts, managed care rebates, and chargebacks processes with Model N's commercial offerings, the company is building a roadmap that extends across the entire Model N Pharmaceutical Suite. As part of its planned deployment schedule, the company will first roll out Model N Government Pricing and Medicaid Claims Processing to gain better visibility and control over its government reimbursement programs. This will be followed by an implementation of the Revenue Planning and Intelligence (RPI) solution, rounding out the company's roadmap with unparalleled revenue planning, risk assessment and business intelligence capabilities.

"Legislative mandates such as the MMA and Medicare Part D have created commercial and government contracting overlaps like never before," said Sujay Jadhav, General Manager of Life Sciences and Vice President at Model N. "Model N has provided its customers with a strong grasp of both sides of contracted business and can deliver a fully integrated revenue management solution that reduces noncompliance risk and ensures bottom-line impact."

About Model N
Model N is a leader in Revenue Management solutions, offering an integrated suite of applications for analytics, pricing strategy and execution, contracts, compliance, and settlements optimized for the industry practices of Life Sciences and High Tech companies. Enabling the creation of a seamless, end-to-end process from price setting through settlements payment, Model N's uniquely integrated approach eliminates revenue leakage and delivers the visibility and controls needed to avoid the risks of non-compliance to government reporting regulations such as Sarbanes-Oxley and government pricing requirements. Customers include: Boston Scientific Corporation; Bristol-Myers Squibb Company; Cypress Semiconductor Corporation; Intersil Corporation; Linear Technology Corporation; Medtronic, Inc.; Microchip Technology, Inc.; Micron Technology Inc.; Ortho-Clinical Diagnostics, a Johnson & Johnson company; ON Semiconductor, Inc. and Pfizer, Inc. Model N is located in Redwood Shores, California. For additional information, visit http://www.modeln.com.


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Megan Reilly
Visit website